1. Search Result
Search Result
Results for "

FOXP3

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

7

Peptides

4

Inhibitory Antibodies

1

Natural
Products

2

Recombinant Proteins

13

Antibodies

1

Click Chemistry

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13624A
    Epirubicin hydrochloride
    Maximum Cited Publications
    36 Publications Verification

    4'-Epidoxorubicin hydrochloride

    DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic Infection Neurological Disease Inflammation/Immunology Cancer
    Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
    Epirubicin hydrochloride
  • HY-13624
    Epirubicin
    Maximum Cited Publications
    36 Publications Verification

    4'-Epidoxorubicin

    DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic Cancer
    Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
    Epirubicin
  • HY-148808

    RXC007

    ROCK Cancer
    Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma [3] .
    Zelasudil
  • HY-126675A
    AS2863619
    5+ Cited Publications

    CDK STAT Inflammation/Immunology
    AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3 + regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene .
    AS2863619
  • HY-P1684
    Peptide P60
    1 Publications Verification

    FOXP3 inhibitor P60

    NF-κB Nuclear Factor of activated T Cells (NFAT) Infection Inflammation/Immunology Cancer
    Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 +CD25 +Foxp3 + T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .
    Peptide P60
  • HY-162943

    PROTACs Cancer
    P60-L3-VHL is a PROTAC-class Foxp3 degrader. P60-L3-VHL reduced cell differentiation and Foxp3 expression in activated Treg cells in vitro and had anti-tumor activity (Blue: E3 ligase ligand (HY-162945); Pink: target protein ligand (HY-162946); Black: linker (HY-162947)) .
    P60-L3-VHL
  • HY-126675
    AS2863619 free base
    5+ Cited Publications

    CDK STAT Inflammation/Immunology
    AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3 + regulatory T (Treg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene .
    AS2863619 free base
  • HY-P991180

    TNF Receptor Cancer
    TRX-518 is a humanized agylcosyl IgG1 anti-GITR mAb, , and is a GITR agonist. TRX-518 binds to the extracellular domain of human GITR, abrogates Treg-mediated suppression. TRX-518 increases effector T cell activation and pro-inflammatory cytokine production, reduces circulating and intratumor Treg frequencies. TRX-518 destabilizes Treg phenotype via Foxp3 downregulation and T-bet upregulation. TRX-518 can be used for the research of solid tumors[1][2][3].
    TRX-518
  • HY-159692

    IONIS-1063734

    TGF-beta/Smad Inflammation/Immunology Cancer
    AZD8701 (IONIS-1063734) is an antisense oligonucleotide targeting FOXP3 in regulatory T cells (Tregs), with a human IC50 of 65.2 nM. AZD8701 binds to intronic sites of all FOXP3 pre-mRNA isoforms and mediates dose-dependent FOXP3 knockdown via free uptake. AZD8701 can be used in cancer-related research .
    AZD8701
  • HY-W107024

    TGF-β Receptor Inflammation/Immunology Cancer
    BMS-986260, an immuno-oncology agent, is a potent, selective, and orally active TGFβR1 inhibitor (IC50=1.6 nM). BMS-986260 displays exquisite selectivity for TGFβR1 over its isozyme TGFβR2, as well as in a panel of more than 200 kinases examined. BMS-986260 inhibits TGFβ mediated nuclear translocation of pSMAD2/3 in MINK and NHLF cells lines with an IC50 of 350 nM and 190 nM, respectively .
    BMS-986260
  • HY-W041608

    NF-κB Toll-like Receptor (TLR) Bacterial Infection Inflammation/Immunology
    Methylchloroisothiazolinone is a widely used fungicide and also an aquatic pollutant with pro-inflammatory activity and neurotoxicity. Methylchloroisothiazolinone induces the production of pro-inflammatory cytokines (such as IL-1β, TNF-α, IL-6) by activating the NF-κB signaling pathway and upregulating TLR4 expression, thereby triggering allergic contact dermatitis. Methylchloroisothiazolinone reduces cholinesterase activity and exacerbates oxidative stress by impairing catalase activity and disrupting redox balance. Methylchloroisothiazolinone poses significant harm to Mediterranean mussels, reducing the viability of hemocytes and digestive gland cells, inhibiting immune phagocytic function, and disrupting osmoregulatory capacity. Methylchloroisothiazolinone is used in studies on allergic contact dermatitis and related immunotoxicity mechanisms .
    Methylchloroisothiazolinone
  • HY-RS05075

    Small Interfering RNA (siRNA) Others

    FOXP3 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FOXP3 Human Pre-designed siRNA Set A
    FOXP3 Human Pre-designed siRNA Set A
  • HY-162946

    Ligands for Target Protein for PROTAC Cancer
    Alkyne-P60 is a potent 15-mer peptide inhibitor of Foxp3. Alkyne-P60 can bind with Foxp3, hinder its nuclear translocation, and diminish Foxp3-mediated inhibition of NFKB and NFAT functions. Alkyne-P60 is a ligand for target protein for PROTAC (HY-162943).
    Alkyne-P60
  • HY-124131
    DS-437
    1 Publications Verification

    Histone Methyltransferase Inflammation/Immunology Cancer
    DS-437 is a dual PRMT5/7 inhibitor (IC50s of PRMT5/7=6 μM). DS-437 is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. DS-437 is a S-adenosylmethionine (SAM)-competitive inhibitor of PRMT5. DS-437 also inhibits DNMT3A and DNMT3B, with IC50s of 52 and 62 μM, respectively. DS-437 inhibits the methylation of FOXP3 .
    DS-437
  • HY-P1453A

    STAT Cancer
    CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development .
    CMD178 TFA
  • HY-13624AR

    4'-Epidoxorubicin hydrochloride (Standard)

    Reference Standards DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic Cancer
    Epirubicin (hydrochloride) (Standard) is the analytical standard of Epirubicin (hydrochloride). This product is intended for research and analytical applications. Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
    Epirubicin hydrochloride (Standard)
  • HY-RS23341

    Small Interfering RNA (siRNA) Others

    Foxp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Foxp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Foxp3 Rat Pre-designed siRNA Set A
    Foxp3 Rat Pre-designed siRNA Set A
  • HY-RS16899

    Small Interfering RNA (siRNA) Others

    Foxp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Foxp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Foxp3 Mouse Pre-designed siRNA Set A
    Foxp3 Mouse Pre-designed siRNA Set A
  • HY-160040

    Toll-like Receptor (TLR) Inflammation/Immunology
    Cobitolimod is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod suppresses Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .
    Cobitolimod
  • HY-159692A

    IONIS-1063734 sodium

    TGF-beta/Smad Inflammation/Immunology Cancer
    AZD8701 (IONIS-1063734) sodium is an antisense oligonucleotide targeting FOXP3 in regulatory T cells (Tregs). AZD8701 sodium can relieve immunosuppression in cancer .
    AZD8701 sodium
  • HY-P11011

    Pep R54; CXCR4 antagonist peptide 19

    CXCR Cancer
    Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC50=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .
    Peptide R54
  • HY-W060417

    Interleukin Related Inflammation/Immunology Cancer
    iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC50 value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4 + and CD8 + T cells, increases regulatory T cell populations, reduces IFN-γ +CD4 + T cell populations, increases Foxp3 +CD4 + regulatory T cell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease .
    iST2-1
  • HY-P1453

    STAT Cancer
    CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits Treg cell development .
    CMD178
  • HY-160040A

    Toll-like Receptor (TLR) Inflammation/Immunology
    Cobitolimod sodium is a DNA oligonucleotide agonist of TLR-9 with anti-inflammatory activity. Cobitolimod sodium inhibits Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .
    Cobitolimod sodium
  • HY-15091

    LF-150195

    Endogenous Metabolite Neurological Disease
    Anisperimus (LF-150195) is an immunosuppressant with the activity of enhancing activation-induced T cell death. Anisperimus enhances the sensitivity of T cells to anti-CD95 antibodies and other inducers by promoting the activation of caspase-8 and caspase-10 at the level of the death-inducing signaling complex (DISC). Anisperimus also promotes the development of Foxp3-expressing regulatory CD4 T cells, thereby preventing central nervous system autoimmunity .
    Anisperimus
  • HY-P10808

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    RSRGVFF (FOXP3 inhibitor P60) is a mixed-type angiotensin-converting enzyme (ACE) inhibitor with blood-brain barrier permeability, boasting an IC50 value of 5.01 μM . RSRGVFF is capable of binding to both active and non-active sites of ACE and its substrate HHL complex, thus reducing the catalytic activity of ACE. RSRGVFF can be further utilized for research on lowering hypertension .
    RSRGVFF
  • HY-162600

    CDK Inflammation/Immunology
    CDK8-IN-15 (Compound 46) is a potent CDK8 inhibitors with an IC50 value of 57 nM. It can enhance the thermal stability of CDK8 along with inhibition against NF-κB and have favourable selectivity across the CDK family and tyrosine kinase. Additionally, it also demostrates a positive effect in vitro psoriasis model induced by TNF-α and alleviats the inflammatory response enhancing the expression of Foxp3 and IL-10, which is promising for research of psoriasis diseases .
    CDK8-IN-15
  • HY-N16465

    Apoptosis Reactive Oxygen Species (ROS) STAT Inflammation/Immunology
    Cinnamtannin D1 is an orally active polyphenolic compound with immunosuppressive activity. Cinnamtannin D1 regulates the balance of Th17/Treg cells by inhibiting AHR expression. Cinnamtannin D1 reduces apoptosis and ROS in INS-1 cells and primary cultured murine islets induced by Palmitic acid (PA) (HY-N0830). Cinnamtannin D1 reduces Th17 cell differentiation via downregulating p-STAT3/RORγt and promotes Treg cell differentiation via upregulating p-STAT5/Foxp3. Cinnamtannin D1 exerts excellent anti-arthritic efficacy in collagen-induced arthritis (CIA) model of mice. Cinnamtannin D1 can be used for the study of rheumatoid arthritis (RA) .
    Cinnamtannin D1
  • HY-P991824

    Transmembrane Glycoprotein Inflammation/Immunology
    Anti-Mouse CD4 Antibody (YTS 177) reacts with the mouse CD4. Anti-Mouse CD4 Antibody (YTS 177) shows non-depleting but binding does induce rapid internalization of CD4 on both CD4 + Foxp3- T cells and Foxp3 + regulatory T cells. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .
    Anti-Mouse CD4 Antibody (YTS 177)
  • HY-122081

    Histone Acetyltransferase LAG-3 CTLA-4 PD-1/PD-L1 Cancer
    CPI-644 is a selective EP300/CBP bromodomain inhibitor, with an IC50 of 0.18 µM against the CBP bromodomain. CPI-644 reduces the proportion of FOXP3 + cells and downregulates the expression of LAG-3, CTLA-4 and PD-1. CPI-644 can be used in cancer-related research .
    CPI-644
  • HY-P990819

    CD28 Neurological Disease Inflammation/Immunology
    Anti-Rat CD28 Antibody (JJ316) is a mouse-derived agonistic IgG1 κ type antibody, targeting to rat CD28. Anti-Rat CD28 Antibody (JJ316) can induce T cell proliferation. Anti-Rat CD28 Antibody (JJ316) can be used for the researches of inflammation, immunology and neurological disease, such as experimental autoimmune encephalomyelitis (EAE) and graft-versus-host disease (GvHD) .
    Anti-Rat CD28 Antibody (JJ316)
  • HY-10540

    AEB071 acetate

    PKC NF-κB Inflammation/Immunology
    Sotrastaurin (AEB071) acetate is a selective, orally active PKC inhibitor. Sotrastaurin acetate inactivates NF-κB by inhibiting PKC α, β, θ, γ subtypes, thereby reducing the transcription levels of immune response-related genes. Sotrastaurin acetate effectively inhibits alloreactive T cell proliferation, conventional T cell activation, as well as the production of pro-inflammatory cytokines and B lymphocytes. Sotrastaurin acetate also maintains the functional and phenotypic stability of regulatory T cells, enhances Foxp3 expression and restores the balance of helper T lymphocytes. Sotrastaurin acetate can prolong the survival time of allografts, and alleviate inflammatory responses and myasthenic symptoms by reducing anti-AChR antibody levels. Sotrastaurin acetate is widely used in studies related to kidney transplantation, psoriasis and myasthenia gravis [3].
    Sotrastaurin acetate
  • HY-P992361

    Transmembrane Glycoprotein Cancer
    HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3 + Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .
    HB0030

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: